Mankind’s profit, revenue miss estimates in Q3, revenue rises 11.5%

Mankind Pharma’s net profit rose 9.5% in the third quarter, below estimates, as revenue rose due to domestic growth and the consolidation of Bharat Serums and Vaccines Ltd (BSV), which it acquired in 2024.

Drug manufacturer’s profits increased ₹414 crore in the three months ending December ₹378 crore a year ago, the company said on Tuesday. Profit decreased by 20.4% respectively. Income increased ₹3,567 crore.

A. Bloomberg A survey of 10 brokerage firms determined Mankind’s net profit as follows: ₹507 crore and income ₹3,607 crore. EBITDA changed little ₹816 crore on a year-on-year basis, while adjusted EBITDA margin fell 170 basis points to 25.9%.

“BSV’s growth initiatives are progressing well with strong double-digit growth in the third quarter,” said the Vice President and General Manager. Rajeev Juneja said in the statement.

Mankind acquired 100% shares of BSV ₹13,768 crore in October 2024, giving the generic drugmaker entry into super-specialty, high-barrier-to-entry products in women’s health, fertility and critical care.

“We remain confident that we will deliver long-term sustainable growth based on four key pillars: stable core business, fast-growing expertise chronic, high potential OTC business and super special BSV portfolio,” said Juneja.

Analysts had expected Mankind’s domestic business to grow thanks to a steady recovery in its core business after the company took corrective measures in FY25, including leadership changes and increased synergies across divisions.

chronic medications

The company focused on increasing the share of its chronic medicine portfolio in total sales. The company stated that the share of chronic drugs increased by 200 basis points to 39.3% in the third quarter, driven by growth of 16.7% in heart drugs and 14.4% in anti-diabetic drugs.

Mankind’s domestic branded pharmaceutical business accounts for the bulk of its overall sales and was up 11.1% year over year. ₹3,046 crore.

Consumer health business unit achieved 5.2% annual growth ₹203 crore is gaining momentum after the decline in Q2 FY26. “We expect growth to improve further,” Juneja said.

Mankind Pharma’s shares gained 4.3 percent in value ₹It was at 2,155.90 at the BSE close on Tuesday. This comes amid a broader market wave following the announcement. India-US trade deal in which the Nifty Pharma index gained 3.02%.